276 214

Cited 0 times in

Sirolimus/steroids Maintenance Therapy after Early Cyclosporine Withdrawal: 12-month Efficacy and Safety Results of Multicenter Single Arm Pilot Study in Primary Renal Allograft Recipients in Korea

Authors
 Man Ki Ju  ;  Duck-Jong Han  ;  Soo Jin Kim  ;  In Sung Moon  ;  Yong Lim Kim  ;  Hyun Chul Kim  ;  Seong Joo Kim  ;  Sang Joon Kim  ;  Soon Il Kim  ;  Yeong Hoon Kim  ;  Chang Kwon Oh  ;  Yu Seun Kim 
Citation
 JOURNAL OF THE KOREAN SURGICAL SOCIETY , Vol.79(4) : 261-266, 2010 
Journal Title
 JOURNAL OF THE KOREAN SURGICAL SOCIETY 
ISSN
 2233-7903 
Issue Date
2010
Keywords
Immunosuppression ; Cyclosporine ; Sirolimus ; Nephrotoxicity
Abstract
Purpose: Sirolimus has potent anti-rejection activity as well as the ability to prolong allograft survival and reduce nephrotoxicity. This study was designed to evaluate the efficacy and safety of sirolimus in Korean de novo renal transplantation. Methods: We included 79 patients who received sirolimus at nine Korean transplantation centers in the intention-to-treat and valid-for-safety analyses. The study was an open, single treatment arm multicenter trial with 12 months of patient follow-up. Initially, patients received 2 mg of sirolimus (after 6 mg of loading does) with cyclosporine and steroids. Sirolimus was administered for up to 12 months. Antibody induction was not used. At 3 months after transplantation, cyclosporine was progressively withdrawn over 4 to 8 weeks while sirolimus was adjusted to obtain trough concentrations within 15∼30 ng/ml up to 6 months and concentrations within 12∼24 ng/ml between 7 and 12 months. Results: The proportion of patients who completed the 12-month sirolimus medication per protocol was 74.7% (59/79). Cyclosporine withdrawal was possible in 64 recipients (81.0%). Fifteen patients discontinued sirolimus before cyclosporine withdrawal, and 5 recipients did so after successful cyclosporine withdrawal. Most common causes of sirolimus discontinuation were graft rejection (n=8). Incidence of biopsy-proven acute rejection within 6 months after transplantation was 15.2%. Patient and graft survival rates at 12 months post transplantation were 97.5% and 96.2%, respectively. During the study period, three graft losses occurred by patient death. Conclusion: Based on this study, cyclosporine and sirolimus induction followed by cyclosporine withdrawal at 3 months post-transplant is considered to be efficient and safe after primary renal transplantation.
Files in This Item:
T201003100.pdf Download
DOI
10.4174/jkss.2010.79.4.261
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Soon Il(김순일) ORCID logo https://orcid.org/0000-0002-0783-7538
Kim, Yu Seun(김유선) ORCID logo https://orcid.org/0000-0002-5105-1567
Joo, Man Ki(주만기) ORCID logo https://orcid.org/0000-0002-4112-7003
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/101980
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse